rss
Ann Rheum Dis 67:1653-1655 doi:10.1136/ard.2008.097006
  • Editorial

The art of medicine in treating osteoarthritis: I will please

  1. J W J Bijlsma,
  2. P M J Welsing
  1. Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
  1. Professor J W J Bijlsma, University Medical Center Utrecht, The Netherlands; J.W.J.Bijlsma{at}umcutrecht.nl
  • Accepted 18 September 2008

The Latin word placebo literally means, “I will please”. Until 1945 the placebo was a “morally” useful but innocuous management tool without curative or symptomatic consequences. When in the 1950s the double-blind randomised controlled trial (RCT) began to establish itself, the placebo was imbued with powerful therapeutic effects and its ethical use in clinical practice was being questioned.1 In a few years the placebo changed from what was called the “humble humbug” (a means of reinforcing a patient’s confidence in his recovery) to an entity with occult-like powers that could mimic potent drugs.

Nowadays placebo is primarily used within the RCT setting; use in clinical practice is generally considered unethical. In the current literature placebo is described as “inert”, “inactive” or “non-specific” and as “dummy” or “sham” treatment in the context of a RCT. An “active” treatment not expected to be useful for the complaints at hand, however, might work on the same principal. When we ask experienced doctors for their opinion on observed placebo effect we receive quite some contradictory responses. Conflicting explanations such as expectation, anxiety relief, faith, patient–doctor relationship, self-perceptions, classic conditioning, symbolic processes, holistic approach, fraud and tricking patients are mentioned among others.

PLACEBO EFFECTS IN OSTEOARTHRITIS

Some of these feelings became apparent in the recent discussion of treatment of osteoarthritis (OA) with glucosamin. A long awaited “definite” trial, the GAIT (Glucosamin/chondroitin Arthritis Intervention Trial) had some remarkable results.2 In this study, patients with symptomatic (with more then half also radiological) knee OA were randomised to five treatment groups: glucosamin, chondroitin sulphate, a combination of glucosamin and chondroitin sulphate, celecoxib and placebo. Primary outcome was a decrease of at least 20% in pain measured by the Western Ontario and McMaster Universities (WOMAC) score. This outcome was reached in 64% of the glucosamin group, 65% of the chondroitin sulphate …

Responses to this article